Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Docosahexaenoic acid (DHA) is an essential omega-3 polyunsaturated fatty acid (PUFA) consisting of a 22-carbon chain with six cis double bonds. It is a primary structural component of the human brain, cerebral cortex, skin, and retina, playing a vital role in neural and visual development. DHA is primarily obtained through dietary sources like fish oil and microalgae or synthesized from alpha-linolenic acid. Pharmacologically, it acts as a pleiotropic signaling molecule that modulates inflammation and lipid metabolism by serving as an agonist for the G-protein coupled receptor FFAR4 (GPR120) and nuclear receptors such as PPARs and RXR-alpha. It is also a precursor to specialized pro-resolving mediators (SPMs) like D-series resolvins. DHA is widely used in infant formula to support neurodevelopment and in clinical settings to manage hypertriglyceridemia and potentially treat sickle cell disease by improving erythrocyte membrane fluidity and reducing vaso-occlusive crises.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docosahexaenoic acid.